ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy

Out of Ignorance 7.78K Followers Follow Summary ARS Pharmaceuticals has experienced a >65% decline since my previous 'Hold' rating, reflecting significant commercialization challenges. SPRY's Q2/2026 report highlights the new CEO's plans to reinvigorate its FDA-approved no-needle epinephrine product, neffy. The company's high-risk profile remains evident, but the high-reward potential is now the more compelling of the two. The new CEO's plans for rigorous cost control along with targeted physician engagement are likely to spur a strong turnaround. Andrii Yalanskyi/iStock via Getty Images This is my second ARS Pharmaceuticals ( SPRY ) article, following 07/2025's "ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine." In No Needle, I rated ARS as a "Hold;" it has since been exercising its high-risk This article was written by Out of Ignorance 7.78K Followers Follow Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences. Analyst’s Disclosure: I/we have a beneficial long position in the shares of SPRY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I may buy additional interests in ARS over the next 72 hours. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.